Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies

AIDS

Volumn 23, Issue 4, 2009, Pages 455-460

  Canducci, Filippo ^a   Sampaolo, Michela ^a   Marinozzi, Maria Chiara ^a   Boeri, Enzo ^b   Spagnuolo, Vincenzo ^b   Galli, Andrea ^b   Castagna, Antonella ^b   Lazzarin, Adriano ^a,b   Clementi, Massimo ^a,b   Gianotti, Nicola ^b  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

HIV 1; Integrase; Raltegravir; Resistance

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; INTEGRASE; LAMIVUDINE; MARAVIROC; RALTEGRAVIR; TENOFOVIR;

ARTICLE; CLINICAL ARTICLE; DNA POLYMORPHISM; GENETIC RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL PROCEDURES; MOLECULAR CLONING; MOLECULAR EVOLUTION; NUCLEOTIDE SEQUENCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT FAILURE; VIRUS GENE; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MUTATION; PYRROLIDINONES; VIRAL LOAD;

EID: 62349120391     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328323da60     Document Type: Article

References (15)

1. Croxtall JD, Lyseng-Williamson KA, Perry CM. Raltegravir. Drugs 2008; 68:131-138.
2. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359:355-365.
3. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354.
4. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007; 369:1261-1269.
5. Moyle C, Gatell J, Perno CF, Ratanasuwan W, Schechter M, Tsoukas C. Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection. AIDS Patient Care STDS 2008; 22:459-471.
6. MacArthur RD, Novak RM. Reviews of antiinfective agents: maraviroc - the first of a new class of antiretroviral agents. Clin Infect Dis 2008; 47:236-241.
7. Geretti AM. Shifting paradigms: the resistance profile of etravirine. J Antimicrob Chemother 2008; 62:643-647.
8. Menzo S, Castagna A, Monachetti A, Hasson H, Danise A, Carini E, et al. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob Agents Chemother 2004; 48:3253-3259.
9. Boeri E, Gianotti N, Canducci F, Hasson H, Giudici B, Castagna A, et al. Evolutionary characteristics of HIV type 1 variants resistant to protease inhibitors in the absence of drug-selective pressure. AIDS Res Hum Retroviruses 2003; 19:1151-1153.
10. Boeri E, Canducci F, Grasso MA, Presi S, Carrera P, Racca S, et al. Phylogenetic internal control for HIV-1 genotypic antiretroviral testing. New Microbiol 2004; 27:105-109.
11. Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 2008; 52:1351-1358.
12. Lataillade M, Chiarella J, Kozal MJ. Natural polymorphism of the HIV-I integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 2007; 12:563-570.
13. Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, Keele BF, et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 2008; 82:3952-3970.
14. Tsurutani N, Kubo M, Maeda Y, Ohashi T, Yamamoto N, Kannagi M, et al. Identification of critical amino acid residues in human immunodeficiency virus type 1 IN required for efficient proviral DNA formation at steps prior to integration in dividing and nondividing cells. J Virol 2000; 74:4795-4806.
15. Hombrouck A, Voet A, Van Remoortel B, Desadeleer C, De Maeyer M, Debyser Z, et al. Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137. Antimicrob Agents Chemother 2008; 52:2069-2078.